Patents by Inventor Stephen P. Wanaski

Stephen P. Wanaski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF ADMINISTERING DEFLAZACORT THERAPY
    Publication number: 20210361676
    Abstract: The disclosure provides a deflazacort therapy comprising, administering to a subject suffering from Duchenne muscular dystrophy (DMD) a fixed dose of deflazacort. Also provided is a deflazacort therapy comprising, increasing the deflazacort dosage when the subject loses ambulation; or, increasing the dosage of deflazacort administered during concomitant administration of a CYP3A4 inducer; or, decreasing the dosage of deflazacort administered during concomitant administration of a CYP3A inhibitor.
    Type: Application
    Filed: August 4, 2021
    Publication date: November 25, 2021
    Inventors: Stephen P. Wanaski, Virginia D. Schmith, Linda L. Grasfeder, Scott Joseph Brantley
  • Methods of administering deflazacort therapy
    Patent number: 11083737
    Abstract: The disclosure provides a deflazacort therapy comprising, administering to a subject suffering from Duchenne muscular dystrophy (DMD) a fixed dose of deflazacort. Also provided is a deflazacort therapy comprising, increasing the deflazacort dosage when the subject loses ambulation; or, increasing the dosage of deflazacort administered during concomitant administration of a CYP3A4 inducer; or, decreasing the dosage of deflazacort administered during concomitant administration of a CYP3A inhibitor.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: August 10, 2021
    Assignee: PTC THERAPEUTICS, INC.
    Inventors: Stephen P. Wanaski, Virginia D. Schmith, Linda L. Grasfeder, Scott Joseph Brantley
  • COMPOSITIONS AND METHODS FOR USING HUPERZINE AND ANALOGS THEREOF
    Publication number: 20150335624
    Abstract: A method of treating a seizure disorder is described wherein an acetylcholinesterase(AChE) inhibitor is administered to a subject having a seizure disorder and an increased risk of a cardiac event from the seizure disorder, wherein the AChE inhibitor decreases the risk of such cardiac event. Further described are methods of decreasing the risk of a cardiac event in subjects with or without a seizure disorder by administering a therapeutically effective amount of an AChE inhibitor. Methods of treating kidney disease and reducing an elevated CRP level by administering an AChE inhibitor are also described.
    Type: Application
    Filed: January 6, 2014
    Publication date: November 26, 2015
    Inventors: Stephen D. COLLINS, Stephen P. WANASKI, Holli A. CARLSON, David KOLB
  • Pharmaceutical compositions and methods of use of lipophilic, silicon-substituted, cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs and derivatives
    Patent number: 7964738
    Abstract: Novel compositions of silicon-substituted carboxylic acid-containing-nonsteroidal anti-inflammatory drugs, their preparation and use in methods for treating, preventing and/or reducing inflammation, pain, angiogenesis, and cortical dementias including Alzheimer's disease, inflammation-related cardiovascular disorders and cancer are described. The compositions and methods are effective at decreasing or reversing the gastrointestinal, renal and other toxicities resulting from the use of non-selective carboxylate-containing-nonsteroidal anti-inflammatory drugs.
    Type: Grant
    Filed: October 20, 2006
    Date of Patent: June 21, 2011
    Assignee: Silamed, Inc.
    Inventors: Stephen Gately, Stephen P. Wanaski